Welcome in NeoVanc
NeoVanc project aims at adapting an off-patent medicine to the specific need of paediatric populations: in specific to develop an optimal dosing and monitoring regimen for vancomycin use in preterm neonates and infants under 3 months of age in order to be able to register it for use in this age group with a PUMA.
This project has been funded with the support of the European Commission under the FP7 programme.
This project has been funded with the support of the European Commission under the FP7 programme.
Login:
Reserved Access to the our services for our Partners.
Latest:
27/11/2021 - News & Events
New study finds no clear benefit from a shorter optimised vancomycin treatment in babies with Gram positive late onset sepsis
PRESS RELEASE
NeoVanc, a European trial featured in The Lancet Child & Adolescent Health, has published the…
Read more12/11/2020 - News & Events
Dr Louise Hill presents sub-study findings at ESPID 2020
Candida and Vancomycin Resistant Enterococcus Colonisation in Septic Neonates on Vancomycin…
Read more07/09/2020 - News & Events
NeoVanc trial in the final stretch towards completion!
The second trial in neonatal sepsis sponsored by Penta is now in its final stretch towards…
Read more